Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
4
×
national blog main
boston blog main
boston top stories
national top stories
boston
clinical trials
deals
europe top stories
gene therapy
new york top stories
roche
san francisco top stories
spinal muscular atrophy
zolgensma
adeno-associated virus
alexandria venture investments
allergan
altitude life science ventures
american society of gene and cell therapy
arch venture partners
billy dunn
biogen
biopharma
boxer capital
crispr
cynthia collins
dravet syndrome
drug prices
drug pricing
drugs
duchenne
ed kaye
editas medicine
encoded therapeutics
europe blog main
evrysdi
fda
gene editing
What
medicine
4
×
therapy
4
×
gene
fda
roche
allergan
approval
approved
atrophy
betting
billion
biopharma
blessing
bosley
ceo
check
clinical
crispr
crude
cusp
cutting
daily
deal
depart
despite
drug
duchenne
edge
editas
editing
effects
encoded
evrysdi
experimental
friday
green
help
historic
home
humans
Language
unset
Current search:
therapy
×
medicine
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
